Lung cancer is a leading cause of death worldwide in both men and women. It represents nearly 1.2 million deaths per year. In recent years, many advances have been made in surgery, chemotherapy and radiation to treat this deadly cancer, but they are unlikely to lead to a cure. Lung cancer is associated with a very poor prognosis. There is therefore an urgent need to develop new therapeutic vaccines to improve the prognosis of this disease. Therapeutic cancer vaccines are designed to regulate host-tumor interactions to shift the balance between tumor acceptance and tumor control. The therapeutic vaccine targets tumor-associated antigen, including cancer testis antigens. KK-LC-1, the antigenic peptide is used in a multipeptide vaccine to target non-small cell lung carcinoma. KK-LC-1 is designated as Kita-kyushu lung cancer antigen 1. This antigen was recently recognized and found to be present in approximately 40 percent of people with lung adenocarcinoma. KK-LC-1 belongs to a family of testicular cancer antigens that are expressed in many cancer tissues but are silent in normal tissues except the testis. This antigen is specifically expressed in a large proportion of lung cancer tissues and not in normal tissues, with the exception of the testes. It should therefore constitute a potential target for immunotherapy. The use of the KK-LC-1 antigenic peptide in a peptide vaccine may prove useful in the treatment of non-cancerous cancers. small cell lung carcinoma which represents 85% of lung cancers. Peptide vaccines specifically target a single epitope. They are safe, non-toxic and easy to formulate. Apart from this peptide, they have good tumor penetration capacity and are biocompatible. Antigenic peptides are determined using bioinformatics tools BLAST and syfpei...... middle of paper ...... al of biomedicine and biotechnology. 1-10.4. Foon, KA et al. (2008). Cancer vaccines: activate the immune system to fight cancer. Oncology problems.5. Winter, H et al. (2011). Specific active immunotherapy for non-small cell lung cancer. Journal of Thoracic Diseases. 3 (2).6. Thundimadathil, J. (2012). Cancer treatment using peptides: current therapies and future prospects. Journal of Amino Acids. 2012, 1-13.7. http://www.bio.davidson.edu/courses/immunology/Students/spring2000/wilson/interleukin12.html8. http://www.rcsed.ac.uk/RCSEDBackIssues/journal/vol46_3/4630007.htm9. http://www4.mpbio.com/ecom/docs/proddata.nsf/5f64ffd4f38c2fda8525645d00769d68/53d2a75653615bab852568cb00572ff310. http://www.mabtech.com/Main/Page.asp?PageId=1611. http://dora.eeap.cwru.edu/vbv/cytokine-elispot-assays.html12. http://www.invivogen.com/docs/Insight_200806.pdfWord count-1595